Oncometabolites in pancreatic cancer: Strategies and its implications

doi:10.5493/wjem.v14.i4.96005

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (852)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

HTML

355

Figures (1-1)

Tables (1-2)

146

Sum=595

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

115

Sum=167

Publishing Process of This Article

Item

Count

Browse

Download

Sum=47

Dec 20, 2024 (publication date) through Dec 24, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Exp Med. Dec 20, 2024; 14(4): 96005
Published online Dec 20, 2024. doi: 10.5493/wjem.v14.i4.96005

Table 2 Overview of inhibitors of metabolism, evaluated through clinical trials in pancreatic cancer

Agent	Target	Combined with	NCT No.
HCQ	Glucose uptake/autophagy	-	NCT01273805
		Gemcitabine	NCT01128296
		Gemcitabine + nab paclitacel	NCT01506973, NCT01978184
		Temuterkib	NCT04386057
		Radiation + capecitabine	NCT01494155
		Chlorphenesin carbamate + mFOLFIRINOX	NCT05083780
		Kinase inhibitors	NCT03825289, NCT05518110, NCT04132505
		Paricalcitol + gemcitabine + nab-paclitaxel	NCT04524702
		Paricalcitol + losartan	NCT05365893
		Leflunomide/bevacizumab	NCT06229340
		CPI-613 + 5-fluorouracil or gemcitabine	NCT05733000
		Paclitaxel protein bound gemcitabine + cisplatin	NCT04669197
2-DG	Glycolysis	Docetaxel	NCT00096707
CPI-613	PDH	mFOLFIRINOX	NCT01835041, NCT03504423
CPI-613	PDH	Gemcitabine + nab-paclitaxel	NCT03435289
Metformin	OXPHOS: Complex I	-	NCT01971034
		Gemcitabine	NCT01210911, NCT02005419
		mFOLFOX-6	NCT01666730
		Stereotactic radiosurgery	NCT02153450
		Rapamycin	NCT02048384
		Gemcitabine + paclitaxel albumin-stabilized nanoparticle formulation	NCT02336087
		Everolimus + octreotide LAR	NCT02294006
IACS-010759	OXPHOS: Complex I	-	NCT03291938
Omeprazole	FASN	-	NCT04930991
Disulfiram	ALDH	Gemcitabine	NCT02671890
Simvastatin	HMG-CoA reductase	Gemcitabine	NCT00944463
		Valproic acid + gemcitabine/nab-paclitaxel-based regimens	NCT05821556
		Metformin + Digoxin	NCT03889795
		Digoxin + Gemcitabine	NCT06030622
		Standard chemotherapy	NCT06241352
Atorvastatin	HMG-CoA reductase	Evolocumab + Ezetimibe	NCT04862260
Opaganib	SK2	-	NCT01488513
Paricalcitol	Lipid metabolism	Liposomal irinotecan + 5-FU/LV	NCT03883919
		Pembrolizumab	NCT03331562
		Gemcitabine + nab-paclitaxel	NCT03520790
ERY-ASP	Asparagine	-	NCT01523808
ERY-ASP	Asparagine	Gemcitabine/FOLFOX	NCT02195180, NCT03665441
Indoximod	IDO	Chemotherapy	NCT02077881
Epacadostat	IDO	Immunotherapy, chemotherapy + GVAX	NCT03006302, NCT03085914
PEG-ADI	Arginine metabolism	Gemcitabine + nab-paclitaxel	NCT02101580
SM-88	Mucin-1 synthesis	-	NCT04229004
SM-88	Mucin-1 synthesis	MPS	NCT03512756

ALDH: Aldehyde dehydrogenase; FASN: Fatty acid synthase; OXPHOS: Oxidative phosphorylation; IDO: Indoleamine 2,3-dioxygenase; PEG-ADI: Pegylated arginine deiminase.

Citation: Maiti A, Mondal S, Choudhury S, Bandopadhyay A, Mukherjee S, Sikdar N. Oncometabolites in pancreatic cancer: Strategies and its implications. World J Exp Med 2024; 14(4): 96005
URL: https://www.wjgnet.com/2220-315x/full/v14/i4/96005.htm
DOI: https://dx.doi.org/10.5493/wjem.v14.i4.96005